Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Biosimilar Testing Services Market Forecast: Value Set To Climb From $2.08 Billion To $3.37 Billion
The biosimilar testing services market size has seen rapid expansion in recent years. It is anticipated to expand from $1.84 billion in 2025 to $2.08 billion in 2026, at a compound annual growth rate (CAGR) of 13.0%. The growth observed historically can be attributed to the broadening of biosimilar development pipelines, an uptick in regulatory approvals for biosimilars, the expansion of biologics manufacturing, an increasing reliance on CRO testing services, and enhancements in analytical testing technologies.
The biosimilar testing services market is poised for significant expansion in the upcoming years. It is forecast to grow to $3.37 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.8%. This anticipated growth during the forecast period is driven by factors such as the increasing demand for economically viable biologic alternatives, the global expansion of biosimilar markets, the escalating complexity of biologic molecules, a heightened focus on comparability studies, and increased investments in biosimilar research and development. Prominent trends for the forecast period include a surging demand for comprehensive analytical characterization, the growing adoption of sophisticated bioanalytical assays, a greater emphasis on testing services that adhere to regulatory standards, the expansion of outsourced support for biosimilar development, and an enhanced focus on method validation and consistency.
Get A Free Sample Report With In-Depth Market Insights:
Biosimilar Testing Services Market Growth Momentum: What Factors Are Shaping Demand?
The anticipated expansion of the biosimilar testing services market is significantly influenced by the increasing occurrence of autoimmune conditions. Autoimmune diseases are characterized by the immune system mistakenly attacking healthy cells and tissues within the body, leading to inflammation and damage. This rising prevalence creates a demand for potent biologic therapies to manage chronic symptoms, reduce flare-ups, and enhance patient outcomes in the long run. Biosimilar testing services play a crucial role by verifying that biosimilars are safe, effective, and comparable to their original biologic counterparts, thereby making these therapeutic options more accessible and affordable. For example, data from Arthritis Australia, an Australian non-profit, indicated in February 2024 that an estimated 562,378 Australians would be living with RA by 2025, representing 14% of all arthritis cases that year. This figure is projected to increase by 33% to 748,721 individuals by 2040, marking an increase of 186,343 Australians with RA from 2025 levels. Consequently, the growing incidence of autoimmune diseases is a key factor propelling the expansion of the biosimilar testing services market.
Biosimilar Testing Services Market Segment Performance And Emerging Opportunities
The biosimilar testing services market covered in this report is segmented –
1) By Service Type: Analytical Testing, Bioanalytical Testing, Stability Testing, Method Development And Validation, Other Service Types
2) By Technology: Cell-Based Assays, Chromatography Techniques, Mass Spectrometry, Bioassays
3) By Molecule Type: Monoclonal Antibodies, Recombinant Hormones, Insulin, Interferons, Enzymes, Other Molecule Types
4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Government Agencies
Subsegments:
1) By Analytical Testing: Protein Characterization, Impurity Profiling, Potency Testing, Glycosylation Analysis, Structural Analysis
2) By Bioanalytical Testing: Pharmacokinetics Analysis, Immunogenicity Testing, Biomarker Analysis, Drug Concentration Measurement, Toxicokinetics Testing
3) By Stability Testing: Long-Term Stability Testing, Accelerated Stability Testing, Stress Testing, Photostability Testing, Temperature Cycling Studies
4) By Method Development And Validation: Analytical Method Development, Bioanalytical Method Development, Method Validation, Process Validation, Assay Development
5) By Other Service Types: Immunogenicity Assessment, Formulation Development, Microbial Testing, Release Testing, Regulatory Consulting
Biosimilar Testing Services Market Trends Redefining Industry Growth
Key players in the biosimilar testing services market are concentrating on expanding their facilities to bring in new technologies or enhanced capabilities, which improves productivity and competitive edge. Facility expansion refers to the action of increasing the size or upgrading existing physical premises or infrastructure to accommodate heightened operational demands or anticipated growth. For instance, in October 2023, Tanvex BioPharma USA Inc., a US-based biotechnology company, unveiled Tanvex CDMO. This modern contract development and manufacturing organization, situated in San Diego, provides comprehensive biologics development and manufacturing services, including cell line development, process optimization, analytical testing, and regulatory support. The aim of this new facility is to hasten the progression of biopharmaceutical products from their conceptual stage to commercial scale, employing advanced technologies and seasoned teams to deliver innovative and transformative biologics to patients across the globe.
Biosimilar Testing Services Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the biosimilar testing services market are Thermo Fisher Scientific Inc., IQVIA Laboratories, Laboratory Corporation of America Holdings, Eurofins Scientific SE, SGS Société Générale de Surveillance SA, WuXi AppTec Co. Ltd., Intertek Group plc, Samsung Biologics Co. Ltd., Almac Group Limited, Syngene International Limited, Shanghai Medicilon Inc., Kymos Group S.L., Pacific BioLabs Inc., Profacgen Inc., ExcellGene SA, BioPharmaSpec Ltd., Charles River Laboratories International Inc., Covance Inc., PPD Inc., ICON plc, Parexel International Corporation, Frontage Laboratories Inc.
View The Full Biosimilar Testing Services Market Report:
Biosimilar Testing Services Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the biosimilar testing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar testing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









